NeoGenomics, Inc. (NEO)

What's Going On With NeoGenomics Stock Tuesday?

NeoGenomics (NASDAQ:NEO) Hits New 12-Month High After Analyst Upgrade

NeoGenomics Announces Executive Leadership and Board of Directors Succession Plan

NeOnc Technologies Announces FDA End of Phase 1 Meeting for NEO212

Omada Health (NASDAQ:OMDA) and NeoGenomics (NASDAQ:NEO) Head-To-Head Contrast

NeoGenomics Highlights NGS, MRD Growth Strategy at Morgan Stanley Conference

NeoGenomics Highlights NGS, MRD Growth Strategy at Morgan Stanley Conference

NeOnc Executives Invest Approximately $629,000 in Open-Market Stock Purchases Following Positive NEO100 Phase 2a Results

Which Is the Better Healthcare ETF: Fidelity's Low-Cost FHLC or First Trust's High-Conviction FBT?

NeOnc Raises $15 Million At Market Adding Fuel to the Strong NEO100 Data

NeoGenomics to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference

NeoGenomics to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference

NeoGenomics (NASDAQ:NEO) Sets New 12-Month High – Here’s What Happened

NeoGenomics Inc (NEO) Stock Up 3.5% but GF Value Says Overvalued -- GF Score: 73/100

NeoGenomics Receives Medicare Coverage for RaDaR ST for Immunotherapy Treatment Response Monitoring

NeoGenomics, Inc. (NEO) Hits Fresh High: Is There Still Room to Run?

NeOnc's NEO100 Phase 2a Brain Cancer Study Beats Historical Benchmark by Nearly 2.5x

NeOnc Technologies Reports Positive Topline Phase 2a Results for Intranasal NEO100 in Recurrent IDH1-Mutant High-Grade Glioma

Neo Performance Materials Q2 Earnings Call Highlights

NeOnc Technologies to Host Investor Conference Call to Discuss Topline Phase 2a Results for Intranasal NEO100 in Recurrent IDH1-Mutant High-Grade Glioma